PARSIPPANY, N.J., Oct. 22, 2014 /PRNewswire-USNewswire/ – Ferring Pharmaceuticals is pleased to announce that the company has acquired DDAVP® (desmopressin acetate) from Sanofi. Ferring is the original developer of the drug desmopressin and has a long-standing history in peptide-based specialty care.
"The return of DDAVP to its roots at Ferring is a welcome addition to our portfolio of products and affirms our commitment to supporting a wide range of disorders with high unmet medical need," said Aaron Graff, President & COO, Ferring Pharmaceuticals Inc. "As a result of this acquisition, distribution of DDAVP will be transferred from Sanofi to Ferring immediately."
DDAVP is available in the following formulations: DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube and DDAVP® Injection.
About DDAVP®
Ferring has a long-standing interest in the area of endocrinology and pediatric urology, which began with the development of desmopressin (desmopressin acetate) in the mid-1970s.
All desmopressin formulations (DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube, and DDAVP® Injection) are approved by the U.S. Food and Drug Administration (FDA).
You are encouraged to report side effects of prescription drugs. Contact Ferring at 1-888-FERRING (1-888-337-7464) or call 1-800-FDA-1088 or visit www.fda.gov/medwatch.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464); visit www.FerringUSA.com.